Sapient leverages NULISA™ panels and assays to capture subtle changes in the low-abundance portion of the proteome, including cytokines, chemokines, and neuroinflammatory mediators.
Sapient is a Certified Service Provider for Alamar Biosciences’ NULISA™ assays on the ARGO® HT System. These assays complement and extend our mass spectrometry-based targeted proteomics services by enabling detection of hard-to-assay cytokines, chemokines, and neuroinflammatory mediators in biofluid samples.
The NULISA platform uses a proprietary sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ligation assays by over a thousand-fold to attomolar levels – allowing for highly quantitative measures of low-abundance proteins that are not amenable to mass spectrometry measure.
Detects 120+ biomarkers of CNS disease, including
neuro-specific proteins.
Through NULISA panels and assays, Sapient can provide highly quantitative measures of low-abundance proteins that are important modulators of immune processes. This complements our mass spectrometry-based (MS) proteomics in several ways by enabling:
Sapient is additionally working closely with Alamar to offer NULISAseq assays under regulated guidance, including CAP/CLIA and GCLP – further extending our multi-omics services for clinical development.
This panel profiles 250+ biomarkers of inflammation and immune response from a single 10μl sample, including low-abundance
cytokines such as IL4, IL5, IL17, and IL33.
With attomolar sensitivity and 12 logs of dynamic range, the panel offers unmatched detectability of the most relevant cytokine and chemokine inflammation targets in blood-based and CSF biofluids.
This panel provides best-in-class sensitivity and robust, multiplexed analysis of 120+ neuro-specific and inflammatory proteins associated with neurodegenerative disorders in plasma and CSF.
The panel includes important proteins such as p-tau217, GFAP, NfL, and alpha- synuclein and enables measure of changes in key inflammatory pathways, supporting protein biomarker discovery and validation for CNS diseases. Results are highly reproducible, with median CV <10%, even at multiplexing scale.
Sapient also offers NULISAqpcr™ single-plex assays with qPCR readout as well as custom development of bespoke assays for your key low-abundance proteins of interest.
Tap our deep expertise in assay development and NULISA technologies to obtain robust measures for difficult-to-assay cytokines, chemokines, and inflammatory mediators.
Learn about Alamar’s novel NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) and how it enables:
For questions or to discuss a specific project, we encourage you to book a time to talk to our scientific team.
"*" indicates required fields
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
